3LEUNG NW,LAI CL,CHANG TT,et al. Extended lamivudinetreatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after 3 years of therapy[J]. Hepatology, 2001,33( 6): 1527-1532.
4BAKER DE. Adefovir dipivoxil focus on its use in the treatment of chronic hepatitis B[J]. Rev Gastroenterol Disord,2005, 5(2):89-100.
5ANNA LE. JENNY H,JAY H,et al. Management of hepatitis B:2000 -summray of worksop [J]. Gastroenterology,2001,7: 1828-1853.
6HADZIYANNIS S,TASSOPOULOS NC,CHANG TY,et al. Long-term adefovir dipiwM1 treatment induces regression of liver fibrosis in patient with HBeAg-negative chronic hepatitis B: resuh after 5 years of therapy[J]. Hepatology,2005,42(suppl 1):754A.
7TENNEY DJ,LEVINE SM,ROSE RE,et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine[J]. Antimicrob Agents Chemother, 2004,48:3498-3507.
2Minde Z,Yimin M,Guangbi Y et al.A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.Hepatology,2006,108-116.
3Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.N Engl J Med,2005,352:2673-2681.
4Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816.
5Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807.
6Peters M,Hann H,Martin P,et al.Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Gastroenterology,2004,126:91-101.
7Perrillo R,Hann H,Mutimer D,et al.Adefovir dipivoxil added to ongloing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.Gastroenterology,2004,126:81-90.
8Hosaka T,Suzuki F,Suzuki Y,et al.Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.Intervirology.2004,47:362-369.
9Jacob JR,Korba BE,Cote PJ,et al.Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model.Antiviral Res.2004,63:115-21.
10Westland CE,Yang H,Delaney WE,et al,437 and 438 Study Teams.Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Hepatology.2003,38:96-103.
4Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
6Ikeda F,Baba N,Takaguchi K. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine:a 5-year study of patients with hepatitis B with lamivudine resistance[J].{H}Journal of Medical Virology,2012,(10):1562-1570.
7Lee YS,Chung YH,Kim JA. rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy[J].{H}Journal of Gastroenterology and Hepatology,2012,(02):300-305.
8Lai HW,Chang CC,Chen TH. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients[J].{H}Journal of the Formosan Medical Association,2012,(08):439-444.
